

Leila E Mansoor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6035884/publications.pdf>

Version: 2024-02-01

21
papers

3,441
citations

840585

11
h-index

752573

20
g-index

22
all docs

22
docs citations

22
times ranked

3435
citing authors

#	ARTICLE	IF	CITATIONS
1	Genital immune cell activation and tenofovir gel efficacy: a case-control study. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	2
2	Transient association between semen exposure and biomarkers of genital inflammation in South African women at risk of HIV infection. <i>Journal of the International AIDS Society</i> , 2021, 24, e25766.	1.2	5
3	Higher mucosal antibody concentrations in women with genital tract inflammation. <i>Scientific Reports</i> , 2021, 11, 23514.	1.6	3
4	The Impact of Semen Exposure on the Immune and Microbial Environments of the Female Genital Tract. <i>Frontiers in Reproductive Health</i> , 2020, 2, .	0.6	4
5	Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa. <i>BMC Infectious Diseases</i> , 2020, 20, 532.	1.3	3
6	Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2019, 22, e25381.	1.2	13
7	HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition. <i>Nature Communications</i> , 2019, 10, 5227.	5.8	40
8	Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. <i>Nature Medicine</i> , 2018, 24, 491-496.	15.2	123
9	Undue inducement: a case study in CAPRISA 008. <i>Journal of Medical Ethics</i> , 2017, 43, 824-828.	1.0	10
10	Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. <i>Science</i> , 2017, 356, 938-945.	6.0	348
11	Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators. <i>AIDS and Behavior</i> , 2017, 21, 462-469.	1.4	1
12	Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. <i>Clinical Infectious Diseases</i> , 2017, 64, 79-82.	2.9	53
13	Social Context of Adherence in an Open-Label 1% Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa. <i>AIDS and Behavior</i> , 2016, 20, 2682-2691.	1.4	12
14	Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 530-539.	13.9	80
15	Genital Inflammation and the Risk of HIV Acquisition in Women. <i>Clinical Infectious Diseases</i> , 2015, 61, 260-269.	2.9	354
16	Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. <i>Trials</i> , 2014, 15, 496.	0.7	9
17	Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 70-85.	1.0	43
18	Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 Trial. <i>AIDS and Behavior</i> , 2014, 18, 849-854.	1.4	44

#	ARTICLE	IF	CITATIONS
19	Safety of Tenofovir Gel, a Vaginal Microbicide, in South African Women: Results of the Caprisa 004 Trial. <i>Antiviral Therapy</i> , 2013, 18, 301-310.	0.6	21
20	Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. <i>Trials</i> , 2011, 12, 67.	0.7	33
21	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. <i>Science</i> , 2010, 329, 1168-1174.	6.0	2,239